Some individuals don’t lose sufficient weight after bariatric surgical procedure, however a brand new examine exhibits that including a every day shot of GLP-1 drug liraglutide might help sufferers shed further kilos and will cut back the necessity for additional surgical procedure.
Bariatric, or weight loss, surgery is very efficient for most individuals with moderate-to-severe weight problems. Research have proven it produces long-term weight reduction and vital enchancment or remission of obesity-related circumstances like type 2 diabetes, hypertension, and sleep apnea.
For round 15% of people that bear bariatric surgical procedure, weight reduction is lower than anticipated, that means that enhancements to well being are, too. A brand new Australian examine has discovered that one of many newer injectable weight-loss medicine, the GLP-1 receptor agonist liraglutide, might help.
“We now have proven that for individuals who regain weight or don’t have an optimum weight reduction impact from bariatric surgical procedure, including in a weight reduction drug will assist them to shed some pounds, usually at a decrease dose than is required in individuals who haven’t had surgical procedure,” stated lead creator Professor Wendy Brown, MD, PhD, head of the Monash College Division of Surgical procedure and Director of the Alfred Hospital’s Esophago-Gastric-Bariatric Unit.
“We’re the primary to point out that the total dose of weight problems administration remedy will not be wanted within the post-bariatric surgical procedure setting, and importantly, high quality of life shouldn’t be affected by introducing the weight problems administration remedy,” Brown continued. “This raises the potential for avoiding dangerous repeat surgical procedure, which is the present principal choice when individuals want extra weight reduction after bariatric surgical procedure.”
The researchers recruited 48 adults aged 20 to 65 who’d undergone one in every of 4 varieties of bariatric surgical procedure (gastric banding, sleeve gastrectomy, one-anastomosis gastric bypass, or Roux-en-Y gastric bypass). Nevertheless, by between 12 and 36 months post-op, these sufferers’ weight reduction was beneath anticipated ranges. Individuals have been randomly assigned to one in every of two teams. One self-injected liraglutide every day (as much as 3 mg, the usual dose); the opposite acquired a placebo injection. The first consequence was the change in physique weight at 12 months. Secondary outcomes included adjustments in blood stress, blood sugar, ldl cholesterol, dietary standing, and high quality of life.
The liraglutide group misplaced a median of 5.7 kg (12.6 lb) after 12 months. On common, the placebo group gained 1.4 kg (3.1 lb). This equals a 7.1-kg (15.6-lb) distinction. Expressed as a share of whole physique weight, this was a few 4.4% discount within the liraglutide group vs a 1.4% acquire within the placebo group.
There have been no vital variations between teams for blood sugar, ldl cholesterol, or dietary markers. As well as, these taking liraglutide had a slight rise in diastolic blood stress (the underside quantity), from 78 to 82 mmHg. When it comes to high quality of life, there have been minor variations between the teams, however no significant total adjustments in wellbeing, temper, or consuming/swallowing consolation.
Most sufferers didn’t attain the total 3-mg dose – the common was round 2.4 mg – however nonetheless achieved vital weight reduction. It’s famous, nonetheless, that no formal knowledge have been collected on why doses weren’t maximized. The authors recommend that both sufferers felt no want to extend additional, or speculated that gentle nausea or gastrointestinal signs could have discouraged dose escalation. It’s well-known that widespread uncomfortable side effects related to liraglutide embody nausea, diarrhea or constipation, and vomiting. Early within the paper, the authors even famous that they excluded contributors who lived greater than an hour away from the hospital in case a gastric band wanted speedy deflation as a result of nausea. Regardless of this, the examine reported no severe adversarial occasions, suggesting that whereas some uncomfortable side effects could have occurred, they have been gentle and manageable.
The researchers famous some examine limitations. Specifically, the small pattern measurement and the truth that not all contributors accomplished the examine. The COVID-19 pandemic and subsequent drug shortages induced lengthy delays and early terminations, disrupting the examine timeline. Most contributors have been feminine and from one Australian medical middle. Many sufferers didn’t attain the total liraglutide dose, so it’s unclear if increased doses may need labored even higher.
Nonetheless, the findings recommend that liraglutide could assist sufferers who plateau or regain weight after bariatric surgical procedure, lowering the necessity for dangerous additional surgical procedures. The examine additionally means that beginning GLP-1 medicine earlier than vital weight regain may enhance outcomes earlier in restoration. The broader implications of the examine are that combining remedy with surgical procedure may at some point type a part of a brand new normal of take care of individuals with weight problems who reply partially to surgical procedure.
“Our demonstration that incretin medicine [such as GLP-1s] improve weight reduction following bariatric surgical procedure supplies nice hope,” stated Professor John Wentworth, MD, PhD, an endocrinologist on the Royal Melbourne Hospital and the examine’s co-corresponding creator. “Excitingly, newer, more practical medicine have turn into accessible and will assist our sufferers obtain even higher weight and well being outcomes.”
“There aren’t any fast fixes, however we now have more and more efficient, evidence-based remedy choices,” added co-author, Adjunct Associate Professor Paul Burton, MD, PhD. “These findings assist a personalised, long-term technique that pairs surgical experience with remedy, way of life assist, and ongoing engagement to attain sturdy remission somewhat than a treatment.”
The examine was revealed within the journal JAMA Network Open.
Supply: Monash University
